TD Cowen analyst Gary Taylor lowered the firm’s price target on Acadia Healthcare (ACHC) to $25 from $44 and keeps a Buy rating on the shares. The firm notes the company’s Q2 results were driven primarily by recognition of TN DPP. Management highlighted lower MDCD volumes and continued pressure at certain facilities, prompting a reduction to the high end of FY25 revenues and adjusted EBITDA guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare: Buy Rating Amid Growth Potential and Operational Challenges
- Acadia Healthcare: Strategic Adjustments and Growth Prospects Justify Buy Rating Amid Medicaid Challenges
- Acadia Healthcare price target lowered to $20 from $28 at Barclays
- Acadia Healthcare Reports Strong Q2 2025 Results
- Acadia Healthcare’s Earnings Call: Growth Amid Challenges